Injection of neutralizing anti-IL-4, -IL-10, or -TGF-β1 antibodies can prevent this tumor-induced functional transition, resulting in enhanced CD8+ CTL generation and protection against tumor growth [74]. The gene discussed is CD8A; the disease is neoplasm.